Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11601957 | 1.00 | ASAH1 (1.00) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL11665159 | 1.00 | ASAH1 (1.00) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL10933495 | 1.00 | ASAH1 (1.00) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL11602950 | 1.00 | ASAH1 (1.00) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL11603162 | 0.99 | ASAH1 (0.97) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL10631384 | 0.96 | ASAH1 (0.93) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL10458638 | 0.95 | ASAH1 (0.90) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL11601229 | 0.89 | ASAH1 (0.80) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL9775183 | 0.88 | ASAH1 (0.79) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL10479199 | 0.87 | ASAH1 (0.77) | ASAH1LMNACYP3A4CYP2D6MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 41201 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137636-A1 | TUMOR-TARGETING THIOCOLCHICINE NANOEMULSION | SMITH HENRY (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| US-12629427-B2 | Nanosystems as selective vehicles | SERVIZO GALEGO DE SAÚDE FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS) | 2026-05-19 | — | — | US | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| CN-122028934-A | Combination of CLDN18_2 antibody and chemotherapeutic drug and application thereof | 江苏奥赛康生物医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | claimed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | claimed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |
| US-4622325-A | Anti-cancer composition for delivering 5-fluorouracil | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1986-11-11 | — | — | US | claimed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | claimed |
| US-4578391-A | Oily compositions of antitumor drugs | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | claimed |
| US-4481203-A | ANTICANCER AGENTS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1984-11-06 | — | — | US | claimed |
| US-4071519-A | 1-Carbamoyl-5-fluorouracil derivatives | MITSUI TOATSU CHEMICALS, INCORPORATED (JA) | 1978-01-31 | — | — | US | claimed |